PacBio has announced its participation in the 1000 Genomes Long Read Sequencing Project, contributing long-read transcriptome data to enhance this significant human genomics initiative. Through ...
MENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has joined the 1000 Genomes Long Read ...
PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson ...
MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare ...
Amit Patel, Ecosystems Director at PacBio, added: “Long-read sequencing plays an important role in generating contiguous, high quality genomes for haplotype phasing, structural variant detection, and ...
PacBio reports that through its partnership with China-headquartered Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical ...
PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research ...
The National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate genomic and epigenomic data from as many as 7,800 participants. The effort will rely on PacBio’s ...
The latest update pegs Pacific Biosciences of California’s fair value at US$2.50 per share, compared with the prior US$2.42 anchor, giving investors a fresh reference point for the story. Analysts are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results